Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: beta-2 adrenoceptor agonists - GlaxoSmithKline/Innoviva

Drug Profile

Research programme: beta-2 adrenoceptor agonists - GlaxoSmithKline/Innoviva

Alternative Names: 293521; 324279; 849117; GSK 293521; GSK 324279; GSK 849117; Horizon programme; LABA programme - GlaxoSmithKline/Innoviva; RELOVAIR programme; THRX-666558

Latest Information Update: 23 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Theravance
  • Developer GlaxoSmithKline; Innoviva
  • Class Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 19 Mar 2010 No development reported - Preclinical for Asthma in USA (Inhalation)
  • 19 Mar 2010 No development reported - Preclinical for Chronic obstructive pulmonary disease in USA (Inhalation)
  • 19 Mar 2010 The generation of development candidates from this research programme appears to have ceased
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top